Daniel F Hayes
Overview
Explore the profile of Daniel F Hayes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
333
Citations
30655
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abdou Y, Barlow W, Gralow J, Meric-Bernstam F, Albain K, Hayes D, et al.
J Natl Cancer Inst
. 2024 Dec;
PMID: 39656951
Background: The phase III RxPONDER trial has impacted treatment for node-positive(1-3), hormone receptor-positive, HER2-negative breast cancer with 21-gene recurrence score (RS) ≤ 25. We investigated how these findings apply to...
2.
Sparano J, Crager M, Gray R, Tang G, Hoag J, Baehner F, et al.
NEJM Evid
. 2024 Jul;
3(8):EVIDoa2300267.
PMID: 39041867
Background: The 21-gene recurrence score (RS) assay (Oncotype DX) is used to guide adjuvant chemotherapy use for patients with hormone receptor-positive, HER2 (human epidermal growth factor receptor 2)-negative, axillary node-negative...
3.
Joyce E, Tao X, Stearns V, Hayes D, Storniolo A, Kidwell K, et al.
Breast Cancer Res Treat
. 2024 Jan;
204(3):539-546.
PMID: 38198070
Purpose: Polypharmacy is associated with negative health outcomes and decreased medication adherence. Polypharmacy is common in cancer populations, but few studies have evaluated the relationship between polypharmacy and aromatase inhibitor...
4.
Cani A, Hayes D
Clin Chem
. 2024 Jan;
70(1):68-80.
PMID: 38175590
Background: Identification and characterization of circulating tumor markers, designated as "liquid biopsies," have greatly impacted the care of cancer patients. Although more recently referring to circulating tumor DNA (ctDNA), the...
5.
Stecklein S, Barlow W, Pusztai L, Timms K, Kennedy R, Logan G, et al.
JCO Precis Oncol
. 2023 Nov;
7:e2300197.
PMID: 37972336
Purpose: Triple-negative breast cancer (TNBC) is a heterogeneous disease. We previously showed that homologous recombination deficiency (HRD) and the DNA damage immune response (DDIR) signature are prognostic in TNBC. We...
6.
Rutherford D, Medley S, Henderson N, Gersch C, Vandenberg T, Albain K, et al.
Pharmacogenomics
. 2023 Aug;
24(12):665-673.
PMID: 37615099
This study tested associations of genotype-predicted activity of CYP3A4, other pharmacogenes, (rs11648166) and (rs28845026) with systemic concentrations of the endocrine therapies anastrozole and fulvestrant in SWOG S0226 trial participants. Participants...
7.
Morikawa A, Li J, Ulintz P, Cheng X, Apfel A, Robinson D, et al.
Cancer Res Commun
. 2023 Jun;
3(6):1093-1103.
PMID: 37377606
Significance: Examining genomic alterations and differentially expressed pathways in brain metastases may inform future therapeutic strategies. This study supports genomically-guided therapy for BCBM and further investigation into incorporating real-time functional...
8.
Wolff A, Somerfield M, Dowsett M, Hammond M, Hayes D, McShane L, et al.
Arch Pathol Lab Med
. 2023 Jun;
147(9):993-1000.
PMID: 37303228
Purpose.—: To update the American Society of Clinical Oncology-College of American Pathologists (ASCO-CAP) recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancer. An Update Panel is...
9.
Wolff A, Somerfield M, Dowsett M, Hammond M, Hayes D, McShane L, et al.
J Clin Oncol
. 2023 Jun;
41(22):3867-3872.
PMID: 37284804
Purpose: To update ASCO-College of American Pathologists (CAP) recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancer. The Panel is aware that a new generation of...
10.
Plichta J, Thomas S, Hayes D, Chavez-MacGregor M, Allison K, De los Santos J, et al.
J Clin Oncol
. 2023 Mar;
41(14):2546-2560.
PMID: 36944149
Purpose: Given the heterogeneity and improvement in outcomes for metastatic breast cancer (MBC), we developed a staging system that refines prognostic estimates for patients with metastatic cancer at the time...